<DOC>
	<DOCNO>NCT00097344</DOCNO>
	<brief_summary>The purpose study determine whether maximal estrogen suppression achieve via combination experimental drug , atamestane , plus FDA-approved drug , toremifene ( Fareston速 ) , effective another approve drug , letrozole ( Femara速 ) , delay growth breast cancer , whether side effect combine hormonal therapy different side effect letrozole .</brief_summary>
	<brief_title>The CAT Study : Atamestane Plus Toremifene Versus Letrozole Advanced Breast Cancer</brief_title>
	<detailed_description>Aromatase enzyme express tissue muscle fat postmenopausal woman . These non-ovarian tissue become dominant source estrogen postmenopausal woman . Breast cancer cell often dependent estrogen continue grow . Atamestane block formation estrogens androgenic precursor body via aromatase enzyme . Toremifene block circulate intracellular estrogen stimulate estrogen receptor breast cancer cell . The goal therapy atamestane , aromatase inhibitor , combination estrogen receptor antagonist , toremifene , achieve complete suppression estrogen stimulation breast cancer cell . This study design determine whether combined hormonal therapy lengthen time disease progression rate objective response , compare single agent therapy approve aromatase inhibitor letrozole .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Hormone-Dependent</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Atamestane</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Women age 18 year old Postmenopausal woman receive first hormonal treatment locally recurrent , locally advanced , metastatic disease , would appropriate candidate treatment antiestrogens aromatase inhibitor . Locally recurrent , locally advanced , locally metastatic disease amenable radiation therapy surgery and/or distant metastatic disease . Pathological histological confirmation primary diagnosis breast cancer time diagnosis advance disease . ECOG performance status 0 , 1 2 Karnofsky performance status 60 high . Predicted life expectancy 12 week . Postmenopausal endocrine status . LH/FSH level postmenopausal range woman whose menopause occur less 5 year ago . At least one tumor localization measurable 2 dimension . One diameter either least 2 cm least two time CT/MRI slice/reconstruction thickness bone/soft tissue/visceral disease assess CT/MRI scan ( include spiral CT technique ) . One diameter least 2 cm lesion bone lesion assess conventional Xray technique . One diameter least 1 cm bone lesion assess conventional Xray technique . Estrogen receptor and/or progesterone receptor positive ( laboratory/institutional standard ) time primary diagnosis determine subsequent biopsy/surgery metastasis . Administration bisphosphonates patient bone metastases allow , long drug start prior randomization patient . Written inform consent obtain . Prior hormonal therapy ( include oophorectomy treatment LH/RH analog ) treat locally recurrent , locally advanced , metastatic disease . Prior chemotherapy treat locally recurrent , locally advanced , metastatic disease . Prior adjuvant therapy aromatase inhibitor antiestrogens/SERMs last dose administer within 3 month prior enrollment . Primary diagnosis disease progression disease therapy antiestrogens ( include SERMs administer prevention osteoporosis ) . Lifethreatening disease require chemotherapeutic intervention . History known CNS metastasis , significant neurological dysfunction include active seizure , clinical sign significant neurological disease . Other active malignancy ( except basal cell carcinoma skin , contralateral breast cancer , situ cervical cancer ) . Patients previous malignancy must without evidence disease least five year . Renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) . Aspartate aminotransferase , alanine aminotransferase , serum bilirubin level 2.5 time upper limit normal . Hemoglobin &lt; 9 g/dL . Platelet count le 100,000 platelet per mm3 . Total white blood cell count le 2,000 cell per mm3 . Premenopausal endocrine status ; pregnant lactating female . Usage investigational drug within thirty ( 30 ) day prior enrollment ; plan usage investigational drug study medication course current study . Contraindication use toremifene , atamestane , letrozole , inactive component formulation state investigator brochure product package insert . Patients unable comply study requirement diagnostic procedure . Prior enrollment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Atamestane</keyword>
	<keyword>Breast neoplasm</keyword>
	<keyword>Combined hormonal therapy</keyword>
	<keyword>Complete estrogen blockade</keyword>
	<keyword>Ductal breast carcinoma</keyword>
	<keyword>Estrogen blocker</keyword>
	<keyword>Fareston速</keyword>
	<keyword>Femara速</keyword>
	<keyword>First line therapy</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Lobular breast carcinoma</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>Locally recurrent breast cancer</keyword>
	<keyword>Maximal estrogen inhibition</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Neoplasms , Hormone-dependent</keyword>
	<keyword>Receptor-positive</keyword>
	<keyword>Stage IIIA breast cancer</keyword>
	<keyword>Stage IIIB breast cancer</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>Toremifene</keyword>
</DOC>